Dysplastic and neoplastic lesions of the cervix, vagina, vulva, and anus have similar risk factors. It is well accepted that persistent infection with high-risk (i.e., oncogenic) human papillomaviruses (HR-HPVs) are required for the development of most of these lesions ( 1 ) . HR-HPV infections are particularly common in young, sexually active women ( 2 ) . Results of cross-sectional studies have revealed that although up to 40% of such women are infected with an HR-HPV, fewer than 10% of infected women develop persistent HPV infections and only 28% of those who do will develop high-grade intraepithelial dysplasia of the cervix within 5 -6 years of the initial infection ( 3 -7 ) . Thus, almost all HR-HPV infections resolve spontaneously without causing clinically relevant dysplastic lesions in the genital tract ( 8 , 9 ) . These epidemiologic features suggest that, although neoplastic trans formation of epithelial cells in the cervix depends on HR-HPV infections, other factors are required to permit pro gression of HR-HPV infections to high-grade lesions and invasive cancer.
The clinical manifestations of dysplastic lesions in the various epithelial regions of the female genital tract (cervix, vagina, and vulva) show remarkable differences. For example, the incidence of cervical intraepithelial neoplasia (CIN) is 10-fold higher than the incidence of dysplastic lesions of the vagina or vulva. Also, the incidence of cervical dysplasia and derived cervical carcinomas peaks approximately 10 years earlier than the incidence of vaginal cancer ( 10 , 11 ) . These observations suggest that, despite the high frequency of HPV infection events in the female lower genital tract, transformation of the vaginal or vulvar epithelium occurs substantially less often than that of the cervical epithelium.
Most vaginal and vulvar lesions occur in women who have a history of HR-HPV -induced cervical dysplasia or carcinomas ( 12 -14 ) . These lesions may arise at the same time (synchronous lesions) or up to several years after the initial cervical lesion (metachronous lesions). Several studies ( 15 -17 ) have demonstrated that women who had had a high-grade cervical lesion or invasive cervical cancer had an increased risk of developing a metachronous cancer within the lower genital tract compared with women in the general population. The existence of both synchronous and metachronous lesions suggests that several independent local infection events induce development of multiclonal dysplastic lesions at distinct anatomic sites. The frequent development of dysplastic lesions in women who have vaginal and vulvar lesions associated with previous cervical disease might refl ect their predisposition for HR-HPV -related lesions compared with the general population. Alternatively, the multicentric lesions might all originate from a distinct epithelial cell population that was infected and transformed by HR-HPVs before being disseminated throughout the epithelium of the genital mucosa. In the latter scenario, all lesions would be expected to be derived from one initially transformed cell clone.
Transformation of epithelial cells by HR-HPVs is mediated by the expression of two viral oncoproteins, E6 and E7. These proteins are required to induce and maintain the transformed phenotype of epithelial cells ( 18 ) . Expression of these viral oncoproteins in epithelial stem cells of the anogenital mucosa also interferes with cell cycle control and with the function of the mitotic spindle apparatus, resulting in severe chromosomal instability and structural and numeric chromosomal aberrations ( 19 -22 ) . As a consequence of such chromosomal instability, the HPV genome may become integrated into the host cell genome by nonhomologous recombination, a feature that char acterizes many high-grade dysplastic lesions and most invasive carcinomas ( 23 -27 ) . HPV DNA integration sites are distributed randomly throughout host-cell genomes ( 27 ) . Thus, the unique junction sequences that are created by the integration of an HPV genome into a host cell genome represent specifi c mo lecular markers for each HR-HPV -induced transformed cell clone ( 28 , 29 ) .
We analyzed viral integration sites in genomic DNA isolated from anatomically independent lesions of the female lower genital tract from individual patients who were previously treated for dysplastic cervical lesions. To examine the clonal origins and relationships among the lesions, we studied samples obtained from patients who fulfi lled the following criteria: those with a previous history of cervical disease who had vaginal or vulvar lesions that featured integrated HPV16 or HPV18 genomes in the primary lesion and for whom archival material of the previous cervical lesions was available. The samples were obtained from women participating in an ongoing clinical study of more than 1500 patients on the frequency of integrated HPV genomes in anogenital lesions ( 24 ) . We identifi ed seven patients who fulfi lled these criteria. Six patients had lesions in the vagina and one patient had a lesion in the vulva. Five patients had a previous history of high-grade squamous intraepithelial lesions (cervical intraepithelial neoplasia grade 2 or higher [ ≥ CIN2]) and two patients had a previous history of squamous cell carcinoma of the cervix.
M ATERIALS AND M ETHODS

Clinical Samples
Vulvar and vaginal biopsy samples were collected from patients with anogenital lesions who were treated in the Departments of Obstetrics and Gynecology at the Universities of Heidelberg and Leipzig and immediately snap frozen in liquid nitrogen. The patients provided written informed consent; this study was approved by the local ethical committees at Heidelberg and Leipzig University. Total genomic DNA was extracted from the fresh-frozen vaginal and vulvar biopsy samples and from archival paraffi n-embedded clinical samples with the use of a DNeasy tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. HPV typing was performed by using the GP5 + / GP6 + polymerase chain reaction (PCR) -enzyme immunoassay method as described by Jacobs et al. ( 30 ) . DNA from frozen tumor samples that were positive for HPV16 or HPV18 was used for the detection of integrated papillomavirus sequences (DIPS) assay (see below). DNA from paraffi n-embedded archival material was used to analyze HPV integration events (IS-PCR assay; see below).
RNA derived from laser-microdissected tissue samples obtained using a MicroBeam laser system (PALM Microlaser Technologies AG, Bernried, Germany) was isolated using an RNeasy RNA isolation kit (Qiagen; Hilden, The Netherlands), and integratespecifi c fusion transcripts were amplifi ed using the amplifi cation of papillomavirus oncogene transcripts (APOT) assay ( 24 ) .
DIPS Assay
DNA isolated from snap-frozen vaginal or vulvar biopsy samples from 21 patients with high-grade vaginal or vulvar lesions and a previous history of cervical disease was subjected to the DIPS assay to analyze whether the HPV16 or HPV18 genome was integrated into the host genome or existed as an episome in the vaginal -vulvar lesions and to determine the exact DNA sequences of the viral -cellular junction sites. The DIPS assay (outlined in Fig. 1 ) is an adaptor ligation -based PCR method designed specifi cally to detect integrated papillomavirus DNA sequences ( 31 ) .
Genomic DNA (0.6 -1.2 mg) was digested with Sau3AI (10 U; New England Biolabs, Beverly, MA) in a volume of 20 μ L in a thermal cycler (GeneAmp 2400; Perkin Elmer, Foster City, CA) at 37 °C overnight, followed by heat inactivation of the enzyme according to the manufacturer's instructions. Double-stranded (ds) adaptors that included recognition sequences for Sau3AI (50 pmol; sequences and formation of the ds adaptor given in Supplemental Table 1 ; available at http://jncicancerspectrum. oxfordjournals.org/jnci/content/vol97/issue24 ) were ligated to Sau3AI-digested genomic DNA by adding T4 DNA ligase (5 U; Roche Mannheim, Germany) and ATP and dithiothreitol (fi nal concentrations of 2 m M each) to the ligation reaction in a total volume of 30 μ L with incubation at 14 °C overnight.
We subjected an aliquot of the ligation products to a fi rst round of linear PCR amplifi cation in a total volume of 25 μ L in a thermal cycler. First-round linear PCR (40 cycles) was carried out in 1× PCR buffer (Gibco BRL, Gaithersburg, MD) containing 1.5 m M MgCl 2 , 200 μ M of each dNTP, 0.2 μ M viral primer I (HPV for I, see Supplemental Table 1 ), 1 U Taq polymerase (Gibco BRL), and 2 μ L of the ligation product. PCR parameters were as follows: initial denaturation at 96 °C for 2 minutes, followed by 40 cycles of denaturation at 96 °C for 30 seconds, primer annealing at the optimal annealing temperature (T a ; see Supplemental Table 1 ) for 30 seconds, and primer extension at 72 °C for 3 minutes, followed by fi nal extension at 72 °C for 7 minutes. For second-round exponential PCR amplifi cation, 2 μ L of the fi rst-round PCR product was subjected to amplifi cation as described above, except that the two primers used were the viral primer II (HPV for II) in Supplemental Table 1 and the adaptor-specifi c primer AP1 reverse, each at 0.4 μ M ), and 30 cycles of PCR were carried out. PCR products were resolved on 2% agarose gels, and the gels were stained with ethidium bromide and viewed by transillumination. To control for DNA quality, we amplifi ed a 1.4-kb genomic locus on chromosome 21 (GenBank accession number AP001068 ) using control primer 1L in the fi rst linear PCR and control primer 2L with primer AP1 reverse in the second exponential PCR.
APOT Assay
Total RNA from laser-microdissected tumor sections (0.1 -0.5 μ g) was reverse transcribed using an oligo(dT) 17 primer coupled to a linker sequence (dT) 17 -p3 ( 24 ) and 50 U of Moloney murine leukemia virus reverse transcriptase (SuperScript, Life Technologies) for 1 hour at 42 °C in a fi nal volume of 20 μ L. To control for RNA integrity and the quality of the fi rst-strand complementary DNAs (cDNAs), total RNA from laser-microdissected tumor sections was also subjected to PCR amplifi cation using glyceraldehyde-3-phosphate dehydrogenase -specifi c oligonucleotide primers, as previously described ( 32 ) . First-strand cDNAs encompassing viral oncogene sequences were subsequently amplifi ed by PCR using an HPV E7-specifi c primer [p1] as the forward primer, p3 as the reverse primer, and 1.5 U of Taq DNA polymerase (Life Technologies) in a total volume of 50 μ L. PCR parameters were as follows: initial denaturation at 94 °C for 2 minutes, followed by 30 cycles of denaturation at 94 °C for 30 seconds, primer annealing at T a (see Supplemental Table 2 ; available at http://jncicancerspectrum.oxfordjournals.org/jnci/ content/vol97/issue24 ) for 30 seconds and primer extension at 72 °C for 3 minutes, followed by fi nal extension at 72 °C for 7 minutes. Primer sequences and optimal PCR T a s are listed in Supplemental Table 2 . We used 5 μ L of amplifi cation product from this fi rst round of PCR as template for the second nested PCR, under identical conditions except that the HPV E7 -specifi c primer [p2] was used as the forward primer and (dT) 17 Table 2 . Nested PCR products were resolved on 2% agarose gels, and the gels were stained with ethidium bromide and viewed by transillumination.
Sequence Analysis of Viral -Cellular Junction Fragments Obtained by DIPS and APOT
PCR products of interest were excised from agarose gels and extracted using a gel extraction kit (Qiagen, Hilden, Germany). The corresponding amplimers were either sequenced directly or cloned with the use of a TA cloning kit (Invitrogen, Carlsbad, CA), and the resulting plasmids were sequenced. Sequencing reactions were performed using a Big-Dye terminator DNAsequencing kit (Perkin Elmer, Boston, MA) and a Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA). Sequence data were analyzed using the BLASTN program (National Center for Biotechnology Information, Bethesda, MD).
Integrate-Specifi c PCR
Archival specimens of the cervical lesions were available for seven of the 21 patients. We used an integrate-specifi c PCR (IS-PCR) assay ( 31 ) to perform a retrospective analysis of specifi c HPV integration events in archival specimens for all seven patients. DNA from paraffi n-embedded archival specimens is usually highly fragmented or damaged by preservation procedures, making amplifi cation of long stretches of DNA (>200 -300 bp) diffi cult. The IS-PCR assay overcomes this problem by using patient-specifi c oligonucleotide primers that are designed using DNA sequence information obtained from PCR products amplifi ed in the DIPS assay from DNA extracted from freshfrozen tissue samples from each patient. Specifi c PCR amplifi cation of integrated HPV DNA sequences was performed using a viral primer (vp) that targeted the HPV DNA sequence and a cellular primer (cp) that targeted the adjacent host DNA of the viral -cellular junction ( Fig. 1 ) . The specifi city of each IS-PCR assay was checked by performing parallel reactions that used DNA isolated from the archival samples of each of the patients and DNA isolated from human cervical cell lines (i.e., SiHa, CaSki, and HeLa cells) that contain HPV16 or HPV18 in their integrated forms as negative controls (data not shown). Also, all PCR amplicons were verifi ed by direct sequencing of the viralcellular junction. The expected amplicon size for the integratespecifi c PCR assay ranged from 153 kb to 184 kb. All DNA samples extracted from archival samples were prescreened for DNA quality by PCR amplifi cation using β -globin -specifi c primers designed to generate an amplifi ed product of 205 bp ( 33 ) . All archival samples obtained from each patient were analyzed by IS-PCR for the presence of unique HPV integration events.
The PCR products were analyzed on 2% agarose gels, and their identities were confi rmed by direct sequencing of the PCR products.
R ESULTS
Identifi cation of Patients With Integrated HPV Genomes in Vaginal -Vulvar Lesions
To examine the clonal origins of anatomically distinct dysplastic lesions in the female lower genital tract, we identifi ed Fig. 1 . Study design. The DIPS polymerase chain reaction (PCR) assay was used to detect papillomavirus sequences ( gray boxes ) that were integrated into genomic cellular sequences ( white boxes ) that was extracted from freshfrozen vaginal and vulvar lesions. Digestion of genomic DNA with Sau3AI was followed by ligation to a double-stranded adaptor that included a recognition sequence for Sau3AI ( black boxes ). Exponential PCR was performed on the ligation product using nested viral primers specifi c for HPV16 or HPV18 (HPV for II, arrow ) and an adaptor-specifi c primer (AP1, arrow ). To determine whether the identifi ed genomic integration loci were expressed in these lesions, we amplifi ed transcripts encoding the viral E6 and E7 oncoproteins by using a previously described ( 24 ) reverse transcription-PCR -based amplifi cation method for papillomavirus oncogene transcripts (APOT assay). RNA was reverse transcribed using an oligo(dT) 17 primer coupled to a linker sequence (dT) 17 -p3. First-strand complementary DNAs encompassing the viral oncogene sequences were subsequently amplifi ed by PCR using an HPV E7 -specifi c primer (E7[p2], arrow ) and poly(T)-p3 as the reverse primer. The sequence information obtained by DIPS was used to design integrate-specifi c PCR (IS-PCR) assays that could be applied to DNA extracted from archival paraffi n-embedded material derived from biopsy samples of cervical lesions. IS-PCR was performed using a viral primer (vp, arrow ) that targeted the HPV sequence and a second primer that corresponded to the adjacent cellular DNA sequences of the viral -cellular junction (cp, arrow ). The expected size of the amplifi cation product was less than 200 bp. 21 patients who had high-grade vaginal or vulvar lesions and a previous history of cervical lesions. Among these 21 patients, 11 had vaginal or vulvar lesions that were positive for integrated HPV16 or HPV18 genomes by the DIPS assay. Archival samples of the cervical lesions were available for only seven of these patients. Among these seven patients, six had vaginal lesions and one had vulvar lesions ( Fig. 2 ) . DIPS analysis revealed that HPV had integrated at a distinct chromosomal locus (i.e., 16p12, Xp22, 1q42, chromosome 7, 17q23, 14q32, and 4q21) in vaginal -vulvar lesions from each of the seven patients. To demonstrate that the identifi ed genomic integration loci were indeed expressed in these cells, we amplifi ed E6/E7 containing transcripts using a previously described reverse transcription-PCR -based amplifi cation of papilloma virus oncogene transcripts (APOT) ( 24 ) . By using the APOT assay, we confi rmed that the identifi ed integrated HPV DNA was actively transcribed in the vaginal -vulvar lesions (data not shown).
Patients' Clinical Histories
The clinical histories of the seven patients whose samples were analyzed in this study are schematically presented in Fig. 2 . Five patients (Cases 1 -5) had a history of high-grade lesions ( ≥ CIN2) of the cervix, and two patients (Cases 6 and 7) had a history of squamous cell carcinoma of the cervix. Four of the fi ve patients with high-grade lesions and the two patients with squamous cell carcinoma underwent hysterectomy, and one patient with a high-grade squamous intraepithelial lesion was treated by cold knife conization. In all cases, histologic evaluation of the surgical specimens showed disease-free R0 resection margins.
Among the fi ve patients who had high-grade lesions of the cervix (three of whom had a grade 3 vaginal intraepithelial neoplasia [VAIN3] and two of whom had a squamous cell carcinoma of the vagina), the fi rst diagnosis of vaginal lesions occurred 38 -143 months after treatment for the cervical lesion. Three patients had several vaginal recurrences during the follow-up period. Among those patients, the period from the fi rst diagnosis of a VAIN3 to progression to invasive vaginal cancer ranged from 53 to 204 months.
The remaining two patients each had a history of squamous cell carcinoma of the cervix (stages pT2b and pT2a, International Federation of Gynecology and Obstetrics [FIGO]). One patient developed a squamous cell carcinoma of the vulva, and the other patient was diagnosed with an invasive carcinoma of the vagina within 6 and 5 years, respectively, after they were treated for cervical carcinoma.
Clonal Relationship Between Multicentric Lesions
To examine the clonal origins of the vaginal and vulvar lesions with respect to the previous cervical lesions, we analyzed whether the cervical lesions had same HPV integration sites as the vaginalvulvar lesions from the same patient. The sequence information obtained with DIPS was used to design IS-PCR assays to verify the presence of integrate-specifi c amplimers in DNA extracted from the archival cervical samples (data summarized in Fig. 2 ) .
In four of the fi ve patients who had a high-grade lesion of the cervix, each of the metachronous vaginal lesions that developed several years after primary therapy for the cervical lesion had an HPV integration site that was identical to that in the cervical lesion ( Fig. 2 ) . In one patient (Case 4), the cervical lesion was IS-PCR negative, even though the cervical lesion was positive for HPV16 DNA. Although the vaginal lesion in this patient may well have emerged from the initial cervical dysplasia, we cannot conclusively establish the clonal relationship between the vaginal lesion and the cervical lesion because of the lack of a specifi c marker for the initial cervical lesion. For another patient (Case 1), biopsy samples taken during two follow-up visits after treatment were histopathologically classifi ed as normal, although both samples contained integrate-specifi c fragments suggestive of residual disease ( Fig. 3 ) . In that patient, the vaginal lesions became clinically apparent as VAIN 3 lesions 11 and 8 months later ( Fig. 2 ) .
For the two patients in the second group (Cases 6 and 7), we found identical HPV integration sites in the primary cervical carcinoma and the subsequently developed vaginal and vulvar carcinomas, respectively.
In summary, these data strongly suggest that all anatomically distinct lesions in the lower genital tract of at least six of seven patients had a common clonal origin with the cervical lesion that was presumably located at the transformation zone of the cervix uteri.
D ISCUSSION
We have previously found that most high-grade cervical lesions and invasive cervical carcinomas are monoclonal with respect to HPV DNA integration sites ( 28 , 29 ) . In this study, we analyzed the clonal relationships among anatomically distinct metachronous lesions by examining the sequences of specifi c HPV DNA integration sites in samples obtained from seven patients who had been diagnosed with vaginal or vulvar carcinoma after being treated for high-grade lesion or carcinoma of the cervix. We found that for six of the seven patients, the viral genome integration sites in metachronic, multifocal vaginal or vulvar lesions were the same as that in the preexisting cervical lesion, suggesting a common clonal origin. We presume that the vulvar and vaginal lesions were derived from quiescent dysplastic HPVtransformed cells that were not detected by the conventional histopathologic analysis because they were locally disseminated early in the neoplastic process. Although all resection margins were reported to be disease free (R0), in six of the seven cases we could detect the identical transformed cell clones in the vulvarvaginal lesions and in the previous cervical lesions. These fi ndings -together with the long intervals observed between the diagnosis of an initial lesion at the cervix and the manifestation of the extracervical lesions and the fact that vaginal lesions occur 10 times less frequently than cervical lesions and primarily in older women -suggest that lower genital tract lesions originate at the transformation zone of the cervix uteri. The data presented here do not allow us to defi ne precisely how the dysplastic cells derived from the cervix reached the independent anatomical sites. Local continuous or discontinuous intraepithelial spread appear to be the most likely mechanisms.
Among the patients whose primary lesions were high-grade lesions of the cervix, the fi rst recurrence in vagina was always a high-grade lesion (i.e., VAIN3) or an invasive carcinoma of the vagina. Minucci et al. ( 34 ) have also reported that the grade of the vaginal abnormality was equal to or more severe than that of the original lesion in the cervix. This fi nding further supports the concept that vaginal and vulvar lesions represent the local progression of preexisting cervical lesions.
Our study has several limitations. Because of the rarity of multicentric lower genital tract lesions and the lack of archival cervical material in many cases, only limited material was available for analysis. Thus, we cannot exclude the possibility that some vaginal or vulvar lesions that develop following cervical dysplasia or cancer represent independent primary lesions at these sites. However, given the high proportion of clonally related lesions in our samples, we believe that a frequent cause of multicentric high-grade dysplasia within the female genital tract is local spreading of a preexisting monoclonal dysplastic cell clone originating at the transformation zone of the cervix. It would be expected that distant spreading of malignant cells occurs only at invasive cancer stages; however, in our study, we showed spreading of transformed cell clones from preinvasive cervical lesions (in four of fi ve CIN3 lesions) to distant sites in the lower genital tract. This early spreading of transformed cells, if supported by results of future studies of more patients, might infl uence the clinical follow-up management of patients who are treated for preinvasive lesions of the cervix. 
